Literature DB >> 16456636

Long-term results after neoadjuvant radiochemotherapy for locally advanced resectable extraperitoneal rectal cancer.

Claudio Coco1, Vincenzo Valentini, Alberto Manno, Claudio Mattana, Alessandro Verbo, Numa Cellini, Maria Antonietta Gambacorta, Marcello Covino, Giovanna Mantini, Francesco Miccichè, Giorgio Pedretti, Luigi Petito, Gianluca Rizzo, Maurizio Cosimelli, Fabrizio Ambesi Impiombato, Aurelio Picciocchi.   

Abstract

PURPOSE: This study was designed to evaluate long-term outcome in locally advanced resectable extraperitoneal rectal cancer treated by preoperative radiochemotherapy.
METHODS: Eighty-three consecutive patients who developed locally advanced resectable extraperitoneal rectal cancer underwent preoperative concomitant radiochemotherapy followed by surgery, including total mesorectal excision.
RESULTS: Median follow-up was 108 (range, 10-169) months. The living patients underwent complete follow-up of, at least, nine years. Fourteen patients developed local recurrence. The time to detection was longer than two years in eight cases and longer than five years in four. Twenty-one patients developed metastases, 19 within the first five years from surgery. At the univariate analysis, clinical stage at presentation, lymph node involvement at clinical restaging after neoadjuvant therapy, and pT and pN stage were found positively correlated to the incidence of metastases. At the multivariate analysis, the only factors which confirmed a positive correlation were pT stage and pN stage. The actuarial overall survival at five, seven, and ten years was 75.5, 67.8, and 60.4 percent, respectively. The same figures for cancer-related survival were 77.9, 70, and 65.8 percent. At the univariate analysis, factors directly correlated with worse survival were: TNM stage at clinical restaging after neoadjuvant therapy (in particular lymph node involvement) pTNM, pT, and pN. At the multivariate analysis the only factors that confirmed a correlation with worse survival were pTNM, pT, and pN.
CONCLUSIONS: Long- term follow-up allows to individuate 28 percent of all local relapses after the first five years from surgery. Postoperative stage is highly predictive of prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16456636     DOI: 10.1007/s10350-005-0291-6

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  10 in total

1.  Preoperative chemoradiotherapy affects postoperative outcomes and functional results in patients treated with transanal endoscopic microsurgery for rectal neoplasms.

Authors:  G Rizzo; D P Pafundi; F Sionne; L D'Agostino; G Pietricola; M A Gambacorta; V Valentini; C Coco
Journal:  Tech Coloproctol       Date:  2021-01-18       Impact factor: 3.781

2.  Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Igor Proscurshim; Fábio G Campos; Wladimir Nadalin; Desiderio Kiss; Joaquim Gama-Rodrigues
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

3.  Long-term surveillance of locally advanced rectal cancer patients with neoadjuvant chemoradiation and aggressive surgical treatment of recurrent disease: a consecutive single-centre experience.

Authors:  Matthias Zitt; Alexander DeVries; Josef Thaler; Reinhold Kafka-Ritsch; Wolfgang Eisterer; Peter Lukas; Dietmar Öfner
Journal:  Int J Colorectal Dis       Date:  2015-08-21       Impact factor: 2.571

4.  Transanal endoscopic microsurgery after neoadjuvant radiochemotherapy for locally advanced extraperitoneal rectal cancer: short-term morbidity and functional outcome.

Authors:  C Coco; G Rizzo; C Mattana; M A Gambacorta; A Verbo; B Barbaro; F M Vecchio; D P Pafundi; M G Mastromarino; V Valentini
Journal:  Surg Endosc       Date:  2013-02-13       Impact factor: 4.584

Review 5.  Risk factors for local recurrence following neoadjuvant chemoradiotherapy for rectal cancers.

Authors:  Jia-Yuan Peng; Zhong-Nan Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

6.  Sphincter-preserving R0 total mesorectal excision with resection of internal genitalia combined with pre- or postoperative chemoradiation for T4 rectal cancer in females.

Authors:  Bartlomiej Szynglarewicz; Rafal Matkowski; Piotr Kasprzak; Daniel Sydor; Jozef Forgacz; Marek Pudelko; Jan Kornafel
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

7.  Preoperative concurrent chemoradiotherapy for locally advanced rectal cancer: treatment outcomes and analysis of prognostic factors.

Authors:  Moonkyoo Kong; Seong Eon Hong; Woo Suk Choi; Si-Young Kim; Jinhyun Choi
Journal:  Cancer Res Treat       Date:  2012-06-30       Impact factor: 4.679

8.  Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth.

Authors:  Ke Zhang; Ye Wang; Xiaoli Yu; Yanyan Shi; Yasai Yao; Xiaofang Wei; Xuezhen Ma
Journal:  BMC Cancer       Date:  2017-12-28       Impact factor: 4.430

9.  Patterns of failure in patients with locally advanced rectal cancer receiving pre-operative or post-operative chemoradiotherapy.

Authors:  Seung-Gu Yeo; Min-Jeong Kim; Dae Yong Kim; Hee Jin Chang; Min Ju Kim; Ji Yeon Baek; Sun Young Kim; Tae Hyun Kim; Ji Won Park; Jae Hwan Oh
Journal:  Radiat Oncol       Date:  2013-05-06       Impact factor: 3.481

10.  Beware of Early Relapse in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy.

Authors:  Seul Gi Oh; In Ja Park; Ji-Hyun Seo; Young Il Kim; Seok-Byung Lim; Chan Wook Kim; Yong Sik Yoon; Jong Lyul Lee; Chang Sik Yu; Jin Cheon Kim
Journal:  Ann Coloproctol       Date:  2020-06-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.